Sucampo Pharmaceuticals — Q1 2015 Earnings Presentation
23 slides from Sucampo Pharmaceuticals's earnings presentation, May 6, 2015
Slide 1: Q1 2015 Corporate Update and Financial Results
Q1 2015 Corporate Update and Financial Results May 6, 2015 $ sucAMPO The Science of Innovation
Slide 2: Forward-Looking Statements
ting Statements Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications € ? SUCAMPO The Science of Innovation
Slide 3: Agenda
Agenda Introductions and Forward-Looking erg Silvia Taylor Statements Corporate Update Peter Greenleaf Pipeline Update Peter Kiener, D. Phil Financial Performance Andrew Smith Closing Remarks Peter Greenleaf $ sucampo 3 The Science of Innovation
Slide 4: Forward-Looking Statements
Forward-Looking Statements This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertaii ities, which may cause results to diffe
Slide 5: Peter Greenleaf
Peter Greenleaf Chief Executive Officer a »* SUCAMPO The Science of Innovation
Slide 6: Q1 2015 Key Highlights
Q1 2015 Key Highlights 1. Demonstrated strong financial performance 2. Continued driving the development of our pipeline 3. Significant progress in evolving our capital structure + Diversified our shareholder base * Significant tax benefit $ sucampo 8 The Science of Innovation
Slide 7: Continued Strong Financial Performance
Continued Strong Financial Performance Significant gains drove strong financial performance + Overall revenue grew 33% + Product royalty revenue from U.S. sales of AMITIZA grew 17% + Product sales revenue of AMITIZA from Japan grew 77% Net income and earnings per share + Net income: $6.4M + Earnings
Slide 8: U.S. AMITIZA Performance
U.S. AMITIZA Performance Sucampo AMITIZA revenue + Royalty revenue grew 17% to $15.7M Takeda AMITIZA net sales* + Increased 17% to $87.5M AMITIZA total prescriptions * March 2015: 121,000 TRx’s, second highest ever + Q1TRx grew 9% YoY + YTD TRx growth 6% + Chronic constipation market (generic and br
Slide 9: Japan AMITIZA Performance
Japan AMITIZA Performance Sucampo revenue * Sales grew 83% to $11.1M Mylan committed to making AMITIZA a success in Japan and building on Abbott’s legacy $ sucampo 9 The Science of Innovation
Slide 10: AMITIZA Rest of World
AMITIZA Rest of World Europe + January: MRP successfully completed + Recommendation for approval in Austria, Belgium, Germany, Italy, Ireland, Luxembourg, the Netherlands and Spain * Ireland, Luxembourg, the Netherlands and Belgium have already issued NMA Canada + Expect NDA decision by end of 2015
Slide 11: Secondary Offering
Secondary Offering Founding shareholders + management executed an underwritten public offering ie 4.6M shares of class Acommon stock Key Benefits . Diversified and expanded our shareholder base . Lowered our corporate tax rate Addressing our capital structure is a key goal for 2015 $ sucampo "1 The
Slide 12: Peter Kiener, D. Phil
Peter Kiener, D. Phil Chief Scientific Officer € 12 3 SUCAMPO The Science of Innovation
Slide 13: At-A-Glance: Sucampo Pipeline
At-A-Glance: Sucampo Pipeline | cunicatrocus | FOCUS STAGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS Lubiprostone — Pediatric Functional t ‘pen-Label Constipation (6 years-17 years) Raper FeI—2H 215 Lena 2016 Lifecycle Management Lubiprostone — Alternate Formulation — Pediatric Functional Constipatio
Slide 14: Diversify Our Science and Portfolio
Diversify Our Science and Portfolio Continue to evaluate external assets * Goal is to enhance and diversify our portfolio through in-licensing or acquisition + Assessment of new therapeutic areas and targets remains ongoing $ sucampo 4 The Science of Innovation
Slide 15: Andrew Smith
Andrew Smith Chief Financial Officer a 5 »* SUCAMPO ‘ The Science of Innovation
Slide 16: Total Revenue, Product Royalty Revenue, Product Sales Revenue
Q1-14 Q1-15 Q1-14 Q1-15 Q1-14 Q1-15 Total Revenue Product Royalty Product Sales Revenue Revenue $sucaMpo © The Science of Innovation
Slide 17: Financial Performance ($M, Non-GAAP)
ncial Performance ($M, Non- GAAP $6.4 Q1-15 Net Income srl $10.6 $3.0 Q1-15 Q1-14 Q1-15 EPS Non-GAAP Earnings $ sucampo 7 The Science of Innovation
Slide 18: COGS, R&D, G&A and S&M Expenses
Q1-14 Q1-15 Q1-14 Q1-15 at: 14 Q1-15 Q1-14 Q1- 15 Cost of Goods Sold R&D Expenses G&A Expenses S&M Expenses $ sucampo 18 The Science of Innovation
Slide 19: Effective Tax Rate
Effective Tax Rate 63% 31% Q1-14 Q1-15 $ sucampo t9 The Science of Innovation
Slide 20: Cash, Cash Equivalents, Restricted Cash and Investments $118.8M
Cash, Cash Equivalents, Restricted Cash and Investments $118.8M Notes Payable $25.8M Cash Flow from Operations $4.6M $ sucampo 20 The Science of Innovation
Slide 21: Peter Greenleaf
Peter Greenleaf Chief Executive Officer ¢ 2 3 SUCAMPO ‘ The Science of Innovation
Slide 22: Continuing to Make Progress on 2015 Expectations
Continuing to Make Progress-on- 2015 Expectations * — Solid financial performance driven by top and bottom line growth ¢ Focus on the advancement of our pipeline * Took significant step in addressing our capital structure, diversifying our shareholder base through the secondary offering $ sucampo 22
Slide 23: e SUCAMPO me
e 3 SUCAMPO me The Science of Innovation
Sucampo Pharmaceuticals — Q1 2015 Earnings Presentation on 6ix